Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising preclinical results.
The post Modified CRISPR tool targets Down syndrome mutation appeared first on
Subscribe to Labiotech.eu’s news feed.
Click on “Follow” and decide if you want to get news from Labiotech.eu via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to Labiotech.eu comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from Labiotech.eu which you are really interested in. Click on the blue “Filter” button below to get started.
Title: Labiotech.eu
Is this your feed? Claim it!
Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising preclinical results.
The post Modified CRISPR tool targets Down syndrome mutation appeared first on
Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. In this episode, Patrick walks us through the company’s DIAGONAL platform, and its lead program DIAG723
The post Diago...
AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.
The post AACR 2026: where is cancer therapeutics heading? appeared first on
Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.
The post PARP inhibitors: a proven class facing limits appeared first on
Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the field.
The post What new atopic dermatitis treatments are in the pipeline in 2026? appeared first on